The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased or otherwise acquired the securities of Juno Therapeutics, Inc. (“Juno” or the “Company”) (Nasdaq:JUNO) between June 4, 2016 and July 7, 2016, inclusive (the “Class Period”).

If you purchased or acquired Juno securities during the Class Period, you may move the Court for appointment as lead plaintiff by no later than September 12, 2016. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the action will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

Juno investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.

Background on the Juno Securities Class Litigation

Juno is a Washington-based biopharmaceutical company that is developing cell-based cancer immunotherapies. Its leading product candidate, JCAR015, is currently in clinical trials.

The action alleges that during the Class Period, Juno made material misrepresentations and omissions about adverse outcomes in the clinical trials of JCAR015. Specifically, the action alleges that Juno failed to disclose that a patient enrolled in Juno’s JCAR015’s Phase 2 trial had died of a cerebral edema in May 2016. Juno was aware that the patient death was important and consulted with the U.S. Food and Drug Administration (“FDA”) about the appropriate response, however it concealed information about the patient’s death from investors.

Instead, in the Company’s June 4, 2016 press release, Juno touted JCAR015’s “[l]ower side effects” and, while partially disclosing that “Grade 3 or higher neurotoxicity was observed in 15/51 (29%) patients” in JCAR015’s Phase 1 trial, the Company did not mention the death of the patient the previous month.

After two other patients died in or around late June or early July, the FDA issued a clinical hold on the JCAR015 Phase 2 trial, which Juno announced after the close of trading on July 7, 2016. In a conference call with analysts that evening, Juno Chief Executive Officer, defendant Hans Bishop, finally revealed that “[t]here was also one previous death from cerebral edema on the trial in May.” On this news, the price of Juno stock fell $13.01 per share, or 31.87%, from a closing price of $40.82 on July 7, 2016, to close at $27.81 per share on July 8, 2016, on extremely heavy trading volume.

In the weeks leading up to these revelations, Bishop and other Juno insiders sold a substantial amount of their Company stock.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, Nashville, and Seattle, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

The National Law Journal has recognized Lieff Cabraser as one of the nation’s top plaintiffs’ law firms for fourteen years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms “representing the best qualities of the plaintiffs’ bar and that demonstrated unusual dedication and creativity.” Best Lawyers and U.S. News have named Lieff Cabraser as a “Law Firm of the Year” for each year the publications have given this award to law firms.

For more information about Lieff Cabraser and the firm’s representation of investors, please visit http://www.lieffcabraser.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.